📰 Rom News
Page 439 - Rom News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rom. Real-time updates on events, politics, business and more.
May 25, 2023
Jose Asumendi from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price remains unchanged at EUR 140. | May 25, 2023
May 25, 2023
Serstech has today received an order of 27.5 MSEK from its partner Proengin Inc in the USA. The order consists of hardware, software and the patented SERS kit and will be delivered and invoiced before... | May 25, 2023
May 25, 2023
In a research note, Deutsche Bank analyst Jaime Rowbotham has maintained his recommendation on the stock with a Buy rating. The target price is revised upwards from GBX 635 to GBX 610. | May 25, 2023
May 25, 2023
Already positive, the research from Bernstein and its analyst Gunther Zechmann still consider the stock as a Buy opportunity. The target price is unchanged at EUR 89. | May 25, 2023
May 25, 2023
Karan Johar who is celebrating his 51st birthday today treated fans with first-look posters of Rocky Aur Rani Ki Prem Kahani featuring Ranveer Singh and Alia Bhatt.
May 25, 2023
Toronto-Dominion Bank on Thursday reported a rise in quarterly profit, as the lender benefited from robust growth in its personal and commercial banking business.... | May 25, 2023
May 25, 2023
New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on... | May 25, 2023
May 25, 2023
Marcus Diebel from JP Morgan retains his negative opinion on the stock with a Sell rating. The target price is decreased from EUR 15.90 to EUR 15.40. | May 25, 2023
May 25, 2023
By Colin Kellaher Canadian Imperial Bank of Commerce on Thursday said its board raised the quarterly dividend by 2.4%, to 87 Canadian cents from C$0.85. The new payout, equal to C$3.48 a... | May 25, 2023
May 25, 2023
New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on